BPGbio Announces Promising Readout from Phase 2a Trial Evaluating BPM 31510 IV for Pancreatic Cancer
BOSTON--(BUSINESS WIRE)--BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced that review of the Phase 2a trial in advanced, refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results